Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins

References

1. Pitt TL. Pseudomonas mallei and P. pseudomallei . In Parker MT, Duerden BI. eds Topley and Wilson's Principles of bacteriology, virology and immunity vol II, 8th edn. Systematic bacteriology. London, Edward Arnold: 1990265–273
   [Google Scholar]
2. Dance DAB. Melioidosis: the tip of the iceberg?. Clin Microbiol Rev 1991; 4:52–60
   [Google Scholar]
3. Currie B. Melioidosis in Papua New Guinea: is it less common than in tropical Australia?. Trans R Soc Trop Med Hyg 1993; 87:417 [CrossRef]
   [Google Scholar]
4. Jenney AWJ, Lum G, Fisher DA, Currie BJ. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents 2001; 17:109–113 [CrossRef]
   [Google Scholar]
5. Vedros NA, Chow D, Liong E. Experimental vaccine against Pseudomonas pseudomallei infections in captive cetaceans. Dis Aqu Org 1988; 5:157–161 [CrossRef]
   [Google Scholar]
6. Dannenberg AM, Scott EM. Melioidosis: pathogenesis and immunity in mice and hamsters.II. Studies with avirulent strains of Malleomyces pseudomallei . Am J Pathol 1958; 34:1099–1121
   [Google Scholar]
7. Levine HB, Maurer RL. Immunisation with an induced avirulent auxotrophic mutant of Pseudomonas pseudomallei . J Immunol 1958; 81:433–438
   [Google Scholar]
8. Brett PJ, Mah DCW, Woods DE. Isolation and characterisation of Pseudomonas pseudomallei flagellin proteins. Infect Immun 1994; 62:1914–1919
   [Google Scholar]
9. Bryan LE, Wong S, Woods DE, Dance DAB, Chaowagul W. Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei . Can J Infect Dis 1994; 5:170–178
   [Google Scholar]
10. Perry MB, MacLean LL, Schollaardt T, Bryan LE, Ho M. Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei . Infect Immun 1995; 63:3348–3352
    [Google Scholar]
11. Charuchaimontri C, Supputtamongkol Y, Nilakul C. et al. Anti-lipopolysaccharide II: an antibody protective against fatal melioidosis. Clin Infect Dis 1999; 29:813–818 [CrossRef]
    [Google Scholar]
12. Kanai K, Kondo E. Recent advances in biomedical sciences of Burkholderia pseudomallei . Jpn J Med Sci Biol 1994; 47:1–45 [CrossRef]
    [Google Scholar]
13. Popov S, Kurilov V, Iakovlev A. Pseudomonas pseudomallei and Pseudomonas mallei are capsule forming bacteria. Zh Mikrobiol Epidemiol Immunobiol 1995; 5:32–36
    [Google Scholar]
14. Puthucheary S, Vadivelu J, Ce-Cile C, Kum-Thong W, Ismail G. Electron microscopic demonstration of extracellular structure of Burkholderia (Pseudomonas) pseudomallei . Am J Trop Med Hyg 1996; 54:313–314
    [Google Scholar]
15. Ahmed K, Encisco H, Masaki H. et al. Attachment of Burkholderia pseudomallei to pharyngeal epithelial cells: a highly pathogenic bacteria with low attachment ability. Am J Trop Med Hyg 1999; 60:90–93
    [Google Scholar]
16. Pruksachartvuthi S, Aswapokee N, Thankerngpol K. Survival of Pseudomonas pseudomallei in human phagocytes. J Med Microbiol 1990; 31:109–114 [CrossRef]
    [Google Scholar]
17. Brett P, Woods D. Pathogenesis of and immunity to melioidosis. Acta Tropica 2000; 74:201–210 [CrossRef]
    [Google Scholar]
18. Reckseidler SL, DeShazer D, Sokol PA, Woods DE. Detection of bacterial virulence genes by subtractive hybridisation: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect Immun 2001; 69:34–44 [CrossRef]
    [Google Scholar]
19. Atkins T, Prior R, Mack K. et al. Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J Med Microbiol 2002; 51:539–547
    [Google Scholar]
20. Chart H. Lipopolysaccharide: isolation and characterisation. In Raton B, Arbor A. eds Methods in practical laboratory bacteriology London: CRC Press; 199411–20
    [Google Scholar]
21. Harlow E, Lane D. Antibodies: a laboratory manual Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1988
    [Google Scholar]
22. Laemmli EK. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 1970; 227:680–685 [CrossRef]
    [Google Scholar]
23. Chart H. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation and resolution of bacterial components. In Raton B, Arbor A. eds Methods in practical laboratory bacteriology London: CRC Press; 199421–33
    [Google Scholar]
24. Steinmetz I, Rohde M, Brenneke B. Purification and characterisation of an exopolysaccharide of Burkholderia (Pseudomonas) pseudomallei . Infect Immun 1995; 63:3959–3965
    [Google Scholar]
25. Russell P, Eley S, Ellis J. et al. Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. J Antimicrob Chemother 2000; 45:813–818 [CrossRef]
    [Google Scholar]
26. Poxton IR, Arbuthnott JP. Determinants of bacterial virulence. In Parker MT, Collier LH. eds Topley and Wilson's Principles of bacteriology, virology and immunity vol I, 8th edn. London, Edward Arnold: 1990332–351
    [Google Scholar]
27. Ho M, Schollaardt T, Smith MD. et al. Specificity and functional activity of anti- Burkholderia pseudomallei polysaccharide antibodies. Infect Immun 1997; 65:3648–3653
    [Google Scholar]
28. Pier GB, Thomas DM. Characterisation of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa . J Infect Dis 1983; 148:206–213 [CrossRef]
    [Google Scholar]
29. Jones AL, Beveridge TJ, Woods DE. Intracellular survival of Burkholderia pseudomallei . Infect Immun 1996; 64:782–790
    [Google Scholar]
30. Santanirand P, Harley VS, Dance DAB, Drasar BS, Bancroft GJ. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei . Infect Immun 1999; 67:3593–3600
    [Google Scholar]
31. Lertmemongkolchai G, Cai G, Hunter CA, Bancroft GJ. Bystander activation of CD8+ T cells contribute to the rapid production of IFN-gamma in response to bacterial pathogens. J Immunol 2001; 166:1097–1105 [CrossRef]
    [Google Scholar]